The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

May 11, 2017 updated by: Nafrialdi, Indonesia University
DLBS1033 is bioactive protein fraction which extracted from Lumbricus rubellus earthworm. This earthworm comes from Pengalengan, West Java, Indonesia. DLBS1033 possesses 8 major proteins with molecular weight below 100 kDa, so its named as Lumbricus Low Molecular weight Proteins (LLP). This enzym can be transported to the bloodstream via intestinal epitel. Structure of DLBS1033 looks like lumbrokinase. Lumbrokinase is enzym that consist of 6 isoenzyme serine protease. As a drug that consists of serin protease enzym, suspected that the mechanism of action of DLBS1033 similar with lumbrokinase, especially as plasminogen activator in fibrinolytic system. In vitro study by Trisina et al showed that DLBS1033 has fibrinogenolytic activities on fibrinogen α, beta, and gamma chain, decreasing platelet aggregation and clotting time was prolonged. Until now, the mechanism of action and effects of DLBS1033 on human fibrinolytic and coagulation system still unknown. Therefore, the aim of this clinical trial is to evaluate the effects of DLBS1033 on human fibrinolytic and coagulation system on healthy subjects.

Study Overview




Intervention / Treatment

Detailed Description

Fibrinolysis is a process to lyse clot formed by thrombin. It starts with activating plasminogen to plasmin by the endogenous tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). These activator are found in the endothelium, granulocytes and monocytes. Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of tPA and uPA) and α2-antiplasmin is major inhibitor of plasmin. Plasmin wil degrade soluble fibrinogen and fibrin to produce fibrinogen degradation products and fibrin degradation products, respectively.

Lumbrokinase has been investigated in animal studies. Kim et al was conducting on rats by administered freeze-dried powder of Lumbricus rubellus earthworm orally. This study showed that earthworm powder is valuable for the prevention and/or treatment of thrombotic conditions. Similar conclusion also shown on study by Lee et al, which compared antithrombotic and fibrinolytic activities of lumbrokinase SPP-501 (extracted from Eisenia andrei earthworm) with urokinase and t-PA in a thrombosis model of rat vena. The results of this study were decreasing of thrombus weight, shortening of euglobulin lysis time (ELT), and reducing platelet aggregation of rat which given SPP-501.

Conclusion from several clinical trial similar with several studies on animal. From study which was conducted by Jin et al on 51 cerebral infarct subjects which were given 3 times 400 mg lumbrokinase (n = 31) or control (n = 20) for 28 days. In the treatment group, kaolin partial thromboplastin time (KPTT) was prolonged, t-PA activity and D-dimer level increase, and fibrinogen decreased significantly. It is concluded that mechanism of lumbrokinase as oral antithrombotic and fibrinolytic are by inhibition of coagulation intrinsic pathway and activate fibrinolytic pathway by increasing t-PA activity. Fibrinolytic activity was also concluded by Rey, who was conducted study on 28 diabetic foot ulcer subjects, which were given 3 times 500 mg lumbrokinase per day (n = 14) for 7 days, or placebo. On this study, in the treatment group mean of D-dimer was increased.

From many clinical trials, it is concluded that effects of lumbrokinase have seen after several days. It is different with intravenous fibrinolytic enzym, such as streptokinase and t-PA, which effects have seen soon after it was used. Therefore oral lumbrokinase could not replace the function of intravenous fibrinolytic enzym,that was used on acute thrombosis. Based on antithrombotic and fibrinolytic activity, lumbrokinase might used as secondary prevention after acute thrombosis, such as myocard infarct and stroke. Some researchers have started clinical trials about that hypothesis.

Pilot study by Kasim et al was used a lumbrokinase in 10 patient with stable angina pectoris. This study showed that 70% of total sample receiving lumbrokinase had a significant decrease in summed stress score of perfusion imaging and better perfusion in viable myocardium after 30 days of lumbrokinase treatment.

Study Type


Enrollment (Actual)



  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Jakarta, Indonesia, 10430
        • Indonesia University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers


Genders Eligible for Study



Inclusion Criteria:

  • Male
  • 18-55 years old
  • body mass index between 18-25 kg/square metres
  • normal physical examination
  • Patient still have the ability to undergo examinations and give written informed consent
  • Plasmin-antiplasmin complex (PAP complex) level between 0-514 ng/ml
  • Platelet aggregation (ADP 10 uM) > 49%

Exclusion Criteria:

  • Patient with cardiovascular disease, hypertension, diabetes mellitus, and dyslipidemia
  • Creatinin serum more than 1,5 x upper limit normal
  • SGOT and SGPT more than 3 x upper limit normal
  • Blood pressure ≥ 140/90 mmHg
  • Fasting blood glucose > 126 mg/dL
  • Alcohol patients
  • Took any medications (including traditional medicine, supplement and vitamin) in 1 week before the study)
  • Patient has bleeding history which unclear etiology
  • Hemoglobin < 10 g/dL
  • Thrombocyte count < 100.000/uL
  • Heavy smoker (Bringman Index > 600)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
Placebo is made with same size and shape with study drug.
Experimental: DLBS1033
The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
Placebo is made with same size and shape with study drug.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
plasmin-antiplasmin complex (PAP complex)
Time Frame: one week
changes in plasmin-antiplasmin complex
one week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
euglobulin clot lysis time (ECLT)
Time Frame: one week
changes in euglobulin clot lysis time
one week
prothrombin time (PT)
Time Frame: one week
changes in prothrombin time
one week
Time Frame: one week
changes in fibrinogen
one week
activated partial thromboplastin time (aPTT)
Time Frame: one week
changes in activated partial thromboplastin time
one week
platelet aggregation
Time Frame: one week
changes in platelet aggregation
one week

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum creatinine
Time Frame: one week
serum creatinine
one week
serum glutamic oxaloacetic transaminase (SGOT)
Time Frame: one week
changes in serum glutamic oxaloacetic transaminase
one week
serum glutamic pyruvic transaminase (SGPT)
Time Frame: one week
changes in serum glutamic pyruvic transminase
one week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.



  • Principal Investigator: Nafrialdi, MD, PhD, SpPD, SpFK, Indonesia University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2012

Primary Completion (Actual)

October 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

September 7, 2012

First Submitted That Met QC Criteria

September 25, 2012

First Posted (Estimate)

September 27, 2012

Study Record Updates

Last Update Posted (Actual)

May 15, 2017

Last Update Submitted That Met QC Criteria

May 11, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?


This information was retrieved directly from the website without any changes. If you have any requests to change, remove or update your study details, please contact As soon as a change is implemented on, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on DLBS1033